Progetto <u>CANOA</u> <u>CARCINOMA</u> <u>ARCINOMA</u> <u>ARC</u>

QUESITO CLINICO 2:

In pazienti con carcinoma mammario HER2-positivo cT1 cN0 è raccomandabile trattamento neoadiuvante con chemioterapia e agente anti-HER2?

Sintesi delle evidenze e problematiche emerse (dal lavoro di gruppo)

Jennifer Foglietta


Ospedale S. Maria- Terni

- P= pazienti con carcinoma mammario HER-2 positivo cT1 cN0
- I= chemioterapia neoadiuvante+anti her2
- C = nessun trattamento neoadiuvante (chir.+adiuvante+ anti HER2)
- O=IDFS, DDFS, OS, qualità di vita e tossicità

Criteri inclusione


- NOHA trial:T>2cm
- NeoSphere: T >2 cm
- HannaH: breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size ≥1 cm
- TRYPHAENA: stage II-III
- BERENICE: T>2 cm se N0
- KRISTINE: T>2 cm
- PEONY: T2-3, N0-1, M0 or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm

Antrhacycline-free regimens: neoadjuvant setting




BrUOG study

clinical stage II-III HER2+ BC



Apt trial



10-year recurrence-free interval was 96·3% (95% Cl 94·3–98·3)

10-year overall survival was 94·3% (95% Cl 91·8–96·8)

10-year breast cancer-specific survival was 98·8% (95% CI 97·6–100).

Tolaney S. at al NEJM 2015; Lancet 2023

Processo di adolopment GRADE




Figura 3 – Tradotta da: Journal of Clinical Epidemiology 2017 81, 101-110DOI: (10.1016/j.jclinepi.2016.09.009) Copyright © 2016 The Author(s) Terms and Conditions



Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde, MD¹; Mark R. Somerfield, PhD²; Lisa A. Carey, MD³; Jennie R. Crews, MD⁴; Neelima Denduluri, MD⁵; E. Shelley Hwang, MD⁶; Seema A. Khan, MD⁷; Sibylle Loibl, MD, PhD⁸; Elizabeth A. Morris, MD⁹; Alejandra Perez, MD¹⁰; Meredith M. Regan, ScD¹¹; Patricia A. Spears, BS³; Preeti K. Sudheendra, MD¹²; W. Fraser Symmans, MD¹³; Rachel L. Yung, MD⁴; Brittany E. Harvey, BS²; and Dawn L. Hershman, MD¹⁴

Recommendation 5.1. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered neoadjuvant therapy with an anthracycline and taxane or non–anthracycline-based regimen in combination with trastuzumab. Pertuzumab may be used with trastuzumab in the neoadjuvant setting (Type: evidence-based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).

Recommendation 5.2. Patients with T1a N0 and T1b N0, HER2-positive disease should not be routinely offered neoadjuvant chemotherapy or anti-HER2 agents outside of a clinical trial (Type: informal consensus; Evidence quality: intermediate; Strength of recommendation: moderate).

Nodal positivity and systemic therapy among patients with clinical T1–T2NO human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts

Anna Weiss $MD^{1,2,3,4}$ | Olga Martínez-Sáez MD, $PhD^{5,6}$ | Adrienne G. Waks $MD^{2,3,7}$ | Alison Laws MD, $MPH^{1,2,3}$ | Monica McGrath BA¹ | Paolo Tarantino $MD^{2,7}$ | Leah Portnow $MD^{2,3,8}$ | Eric Winer $MD^{2,3,7,9}$ | María Rey $MD^{5,6}$ | Marta Tapia MD^{10} | Aleix Prat MD, $PhD^{5,6}$ | Ann H. Partridge MD, $MPH^{2,3,7}$ | Sara M. Tolaney MD, $MPH^{2,3,7}$ | Juan M. Cejalvo MD, $PhD^{10,11}$ | Elizabeth A. Mittendorf MD, PhD, $MHCM^{1,2,3}$ | Tari A. King $MD^{1,2,3}$

- Registro Dana Farber (dal 2015-2020) n=579

- Registro spagnolo (Barcellona+Valencia) (2012-2021) n=292


Dati solo Dana Farber

		Absolute Effect		
Outcomes	Plain language statements	With With Over no neoadjuvant neoadjuvant treatment chemotherapy and anti-HER2	Relative effect (95% CI)	Certainty of the evidence GRADE
Death	Click here to add summary	With no neoad- juvant treatmentWith neoadju- vant chemother- apy and anti- HER2 1 out of1 out of 100 pa- tients will de- velop an out- come and 99 would not.HER2 1 out of 100 patients will develop an out- come and 99 would not.Close ▼Difference: The difference between how many patients will develop an outcome with neoadjuvant chemotherapy and anti-HER2 and 	<u>RR</u> 1.16 (0.2 to 6.9)	URY LOW VERY LOW Due to serious risk of bias. Due to serious imprecision.
		Confidence interval: Due to the play of chance, there is uncertainty about this difference. The 95%		
		confidence interval is from 1 fewer to 5 more patients		


Recurrence

Dati solo Dana Farber

Should neoadjuvant cher	ould neoadjuvant chemotherapy and anti-HER2 vs. no neoadjuvant treatment be used for HER2 positive cT1 cNo breast cancer patients?				
Outcomes	Plain language statements	Absolute Effect With With no neoadjuvant neoadjuvant treatment chemotherapy and anti-HER2	Relative effect (95% CI)	Certainty of the evidence GRADE	
Death					
Recurrence	Click here to add summary	With no neoad- juvant treatment 1 out of 100 pa- tients will de- velop an out- come and 99 would not. Close ~ Difference: The difference between how many patients will develop an outcome with neoadjuvant chemotherapy and anti-HER2 and with no neoadjuvant treatment is 0 fewer patients out of 100	<u>RR</u> 1.05 (0.25 to 4.34)	●OOO VERY LOW Due to serious risk of bias. Due to serious indirectness. Due to serious imprecision.	
		Confidence interval: Due to the play of chance, there is uncertainty about this difference. The 95% confidence interval is from 1 fewer			
		to 5 more patients			



Axillary lymph node dissection




II.	_	Chauld manadi			and anti LICD	2	Concerns the extension	the used for	LIEDD -	T1	able breast a	ancer patients?
	$\mathbf{\nabla}$	Should neoad	juvant che	mounerapy a	anu anu-merk	z vs. no neoac	ijuvani ureatmen	t be used for	HERZ L	positive CLT	CINO DI BASLIO	ancer patients:

🔵 Bottom panel 🖈 Explanations

▶ Death				
Recurrence				
axillary lymph node dissection				
nodal involvement	Click here to add summary	With no neoad- juvant treatment 18 out of 100 patients will de- velop an out- come and 82 would not. Close - Difference: The difference between how many patients will develop an outcome with neoadjuvant chemotherapy and anti-HER2 and with no neoadjuvant theorement is 4 fewer patients out of 100 Confidence interval: Due to the play of chance, there is uncertainty about this difference. The 95% confidence interval is from 10 fewer to 5 more patients	<u>RR</u> 0.76 (0.45 to 1.29)	VERY LOW Due to serious risk of bias. Due to serious imprecision.

Nodal involvement



Should www vs. eeee be us	sed for [Problema di salute e/o d	i popolazione]?					Bottom panel	🖈 Explanations
CRITERIA			SUM	MMARY OF JUDGEMENTS			I	MPORTANCE FOR DECIS
PROBLEM	No	Probably no	0	Probably yes	Yes			
DESIRABLE EFFECTS	Trivial	Small		Moderate	Large			
UNDESIRABLE EFFECTS	Large	Moderate)	Small	Trivial			
CERTAINTY OF EVIDENCE	Very low	Low		Moderate	High			
VALUES	Important uncertainty or variabilit	Possibly important un variability	certainty or Probably no	important uncertainty or No in variability	nportant uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention			
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know	
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Very low	Low		Moderate	High	No inclu	ded studies	
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies		
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased			
ACCEPTABILITY	No	Probably no		Probably yes	Yes			
FEASIBILITY	No	Probably no		Probably yes	Yes			

Raccomandazione: condizionata a sfavore con certezza delle prove molto bassa

NAT in cT1 cN0 non dovrebbe essere presa in considerazione come prima opzione